PPT-Pravastatin in Elderly Individuals at Risk of Vascular Dise

Presented at Late Breaking Clinical Trials AHA 2002 PROSPER PROSPER 5804 highrisk elderly patients Age 7082 years Preexisting vascular disease coronary cerebral or peripheral Highrisk for vascular disease smoking hypertension or diabetes. Appropriate here you ll be able to find at the same time as download Dise o de escaparates eBook Weve got ebooks for every single subject Dise o de escaparates accessible for download free of charge Search the website at the same time as locate Cris Proper right here it is possible to locate too as download Dise o arquitect nico eBook Weve ebooks for each and every subject Dise o arquitect nico obtainable for download free of charge Search the web site as well as find Abb Michel Andr eBook in p Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. . JAMA 2002;288:2998-3007. ALLHAT- LLT. 10,355 patients with moderate hypercholesterolemia . All patients enrolled in the ALLHAT antihypertensive trial. James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher G. Isles., M.D., A. Ross Lorimer, M.D., Peter W. Macfarlane, Ph. D., James H. McKillop, M.D., and Christopher J. Packard, D. Sc., for the West of Scotland Coronary Prevention Study Group. Why is it Important?. The . A. lberta . C. oalition for . Preven. TION. and Control of Vascular Disease (. ACTION. ) Network . June 5, 2015. Vascular Risk Reduction (VRR). Welcome!. Presentation & Activities. Presented at Late Breaking Clinical Trials. AHA 2002. PROSPER. PROSPER. 5,804 high-risk elderly patients . Age 70–82 years. Pre-existing vascular disease (coronary, cerebral, or peripheral) . High-risk for vascular disease (smoking, hypertension, or diabetes). James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher G. Isles., M.D., A. Ross Lorimer, M.D., Peter W. Macfarlane, Ph. D., James H. McKillop, M.D., and Christopher J. Packard, D. Sc., for the West of Scotland Coronary Prevention Study Group. Identifying Vascular Risk. Vascular Risk Reduction (VRR). Welcome!. Presentation & Activities. Focus: Work together to discover ways to best implement vascular risk identification into your practice. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. . JAMA 2002;288:2998-3007. ALLHAT- LLT. 10,355 patients with moderate hypercholesterolemia . All patients enrolled in the ALLHAT antihypertensive trial. Karen Birmingham, PharmD, BCPS. Specialty Clinical Pharmacy Services. Group Health. “Quote”worthy Definitions. Aging. “Progressive accumulation . of random changes”. “Time-related loss of. yo. Patient). A 88 . yo. man with hypertension, COPD, . atrial. fibrillation presents with severe CP and is diagnosed with a NSTEMI. He is found to have 90% LAD occlusion and receives a drug eluting stent. Current meds: . CENGIZ OZYURT,B., BILGIN B., OZCAN . C.. Celal. . Bayar University Faculty of Medicine Public Health . Department. Elder. . abuse. is a . single. . or. . repeated. . act. , . or. . lack. of . May 25, 2013. Mala Joneja, MD MEd FRCPC . Identify factors that contribute to risk in the medical treatment of Rheumatic Diseases in the elderly population. Identify risks associated with specific pharmacological interventions in the elderly. College of Medicine. King Saud . University. Effects of pravastatin or 12/15 . lipoxygenase. . pathway inhibitors . on indices of diabetic nephropathy in . an experimental . model of diabetic renal disease.